Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01378156 | A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART | PHASE1 | COMPLETED | 9 | — | — | Jun 1, 2010 | May 1, 2014 | Nov 13, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| JS7 plasmid DNA and MVA62B vaccine | BIOLOGICAL | JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25) |